Iovance Biotherapeutics (IOVA) Other Working Capital Changes (2011 - 2026)

Iovance Biotherapeutics (IOVA) has reported Other Working Capital Changes for 8 consecutive years, with -$2.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Working Capital Changes rose 34.89% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$9.8 million (up 20.84% YoY), while the FY2025 annual figure was -$10.9 million, up 9.72% from the prior year.
• Other Working Capital Changes grew to -$2.0 million in Q1 2026 per IOVA's latest filing, from -$2.9 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $6.9 million in Q2 2025 and bottomed at -$5.9 million in Q1 2024.
• Historically, Other Working Capital Changes has averaged $1.4 million across 5 years, with a median of $2.3 million in 2022.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes soared 150.22% — and 2023, when it tumbled 1369.81%.
• Iovance Biotherapeutics' Other Working Capital Changes stood at -$2.3 million in 2022, then retreated by 17.85% to -$2.7 million in 2023, then plunged by 34.23% to -$3.7 million in 2024, then grew by 20.57% to -$2.9 million in 2025, then surged by 30.1% to -$2.0 million in 2026.
• Business Quant data shows IOVA's Other Working Capital Changes at -$2.0 million in Q1 2026, -$2.9 million in Q4 2025, and -$2.4 million in Q3 2025.